Bisphosphonates in the prevention of bone metastases: Current evidence

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 11, 2001, Pages 75-80

  Diel, Ingo J ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; IBANDRONIC ACID; METHOTREXATE; PAMIDRONIC ACID; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; FOLLOW UP; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0034854065     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.25429     Document Type: Conference Paper

References (25)

1. Skeletal complications of malignancy
2. Current use of bisphosphonates in oncology
3. Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastasis
4. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
5. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
6. Palliative pamidronate treatment in patients with bone metastases from breast cancer
7. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
8. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
9. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
10. Efficacy of pamidronate in reducing skeletal events in patients with advanced myeloma
11. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
12. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
13. Clodronate for osteolytic metastases due to breast cancer
14. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
15. Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate
16. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
17. Bisphosphonates and the prevention of metastases. First evidence from preclinical and clinical studies
18. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system
19. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
20. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis
21. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
22. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer
23. Bisphosphonates in the prevention of metastases in breast cancer-results of the extended follow-up study
24. No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients
25. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer